EVAN GLOVER: Open Payments
NPI 1366912230 · LAKEWOOD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,390 in 102 payments from 18 companies in 2025. Trend: 2023 $1,462 · 2024 $1,819 · 2025 $2,390
Food & beverage: $2,390
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 22 | $873 |
| ViiV Healthcare Company | 20 | $479 |
| ABBVIE INC. | 29 | $428 |
| Otsuka America Pharmaceutical, Inc. | 6 | $117 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $61 |
| Merck Sharp & Dohme LLC | 2 | $60 |
| AstraZeneca Pharmaceuticals LP | 3 | $53 |
| Aimmune Therapeutics, Inc. | 3 | $47 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| PFIZER INC. | 2 | $42 |
Products named: VRAYLAR, DOVATO, APRETUDE, REXULTI, QULIPTA, Biktarvy, CAPLYTA, PIFELTRO.
Industry payments across CO — which companies pay providers there.
